Efficacy of Rapamycine cervifo-facial lymphatic malformations

Efficacy of Rapamycine (Sirolimus) in poor prognosis cervifo-facial lymphatic malformations - RAPAMALYMPH

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2013-002800-15-FR

Enrollment

Registered

2015-09-25

Start date

2015-10-13

Completion date

Unknown

Last updated

2024-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 18.0 Level: PT Classification code 10058949 Term: Cystic lymphangioma System Organ Class: 10010331 - Congenital, familial and genetic disorders

Interventions

Product Name: Rapamune 1 mg/ ml solution buvable Pharmaceutical Form: Oral solution INN or Proposed INN: SIROLIMUS CAS Number: 53123-88-9

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

France

Contacts

Public ContactRégis FIEVE

Délégation à la Recherche Clinique et à l’innovation

drc@chru-lille.fr003303 20 44 41 45

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026